Stockscreener 앱 받기
4.23
1.86%
-0.08
시간 외 거래:
4.15
-0.08
-1.89%
전일 마감가:
$4.31
열려 있는:
$4.22
하루 거래량:
965.57K
Relative Volume:
0.38
시가총액:
$250.33M
수익:
$14.79M
순이익/손실:
$-102.44M
주가수익비율:
-1.3914
EPS:
-3.04
순현금흐름:
$-91.73M
1주 성능:
+30.96%
1개월 성능:
+35.79%
6개월 성능:
-28.79%
1년 성능:
-58.12%
1일 변동 폭
$3.94
$4.35
1주일 범위
$3.01
$4.35
52주 변동 폭
$2.45
$10.99
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
4.23 | 250.33M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences Expands Team: 81,000 RSUs Awarded to 7 Strategic New Hires - Stock Titan
Solid Biosciences to Participate at The Citizens Life Sciences Conference - The Manila Times
Exclusive: Solid Biosciences CEO Ready to Reveal Latest Company Vision at Major Life Sciences Event - Stock Titan
Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting - The Manila Times
Solid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual Meeting - Nasdaq
Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting - GlobeNewswire
New Duchenne Treatment Breakthrough: Solid Bio Unveils Critical Gene Therapy Trial Results at Major Conference - Stock Titan
Montai Therapeutics Appoints Allison Bogosian, JD, as Chief People and Administrative Officer - Business Wire
Piper Sandler Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Certain Restricted Stock Units of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain Common Stock of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Solid Biosciences stock hits 52-week low at $2.47 By Investing.com - Investing.com South Africa
Solid Biosciences stock hits 52-week low at $2.47 - Investing.com Australia
Can Solid Biosciences Challenge Sarepta in the DMD Market? - MSN
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space - Seeking Alpha
Solid Biosciences stock hits 52-week low at $2.88 - Investing.com Australia
Solid Biosciences stock hits 52-week low at $2.88 By Investing.com - Investing.com South Africa
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Exclusive Access: Solid Biosciences Leadership Team Headlines Two Major Healthcare Conferences - Stock Titan
Solid Biosciences reports inducement grants under Nasdaq listing rule - TipRanks
Solid Biosciences Expands Team with 43,374 RSU Grants in Strategic Hiring Move - Stock Titan
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Truist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences Inc.'s (NASDAQ:SLDB) market cap dropped US$53m last week; Private equity firms bore the brunt - simplywall.st
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges - Yahoo Finance
Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month - Insider Monkey
Solid Biosciences director Kahn Clare buys $9,924 in stock - Investing.com India
Solid Biosciences director Kahn Clare buys $9,924 in stock By Investing.com - Investing.com Australia
Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update - Defense World
Q1 EPS Forecast for Solid Biosciences Boosted by Analyst - Defense World
Top 10 Insider Purchases Last Month - Insider Monkey
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewswire
Solid Biosciences Inc. to Present Phase 1/2 INSPIRE DUCHENNE Trial Data on SGT-003 Gene Therapy for Duchenne Muscular Dystrophy at 2025 MDA Conference - Nasdaq
Breakthrough DMD Gene Therapy Results: Solid Bio Reveals INSPIRE Trial Data at Major Conference - StockTitan
SLDBSolid Bioscience Latest Stock News & Market Updates - Stock Titan
Solid Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Solid Biosciences Inc. (NASDAQ:SLDB) Shares Acquired by Rhumbline Advisers - Defense World
HC Wainwright Issues Positive Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World
Solid Biosciences shares leap on raised price target to $20 By Investing.com - Investing.com Canada
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):